Nothing Special   »   [go: up one dir, main page]

Wójcik, 2000 - Google Patents

Ubiquitin-and proteasome-dependent pathway of protein degradation as an emerging therapeutic target

Wójcik, 2000

Document ID
9033568128105887006
Author
Wójcik C
Publication year
Publication venue
Emerging Therapeutic Targets

External Links

Snippet

The majority of cellular proteins are degraded by the ubiquitin-and proteasome-dependent proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell cycle, apoptosis, gene expression, angiogenesis, antigen presentation, inflammation …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Caldeira et al. Role of the ubiquitin–proteasome system in brain ischemia: Friend or foe?
Gaczynska et al. Caretaker or undertaker? The role of the proteasome in aging
Amerik et al. Mechanism and function of deubiquitinating enzymes
Borissenko et al. 20S proteasome and its inhibitors: crystallographic knowledge for drug development
Doherty et al. The ubiquitin-proteasome pathway of intracellular proteolysis
US7517529B2 (en) Treatment of type I diabetes
van der Veen et al. Ubiquitin-like proteins
Gabelloni et al. Mechanisms regulating neutrophil survival and cell death
US20090156471A1 (en) Use of anti-amyloid agents for treating and typing pathogen infections
O'Brien et al. Prospects for caspase inhibitors
Xi et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases
Bijlmakers Ubiquitination and the proteasome as drug targets in trypanosomatid diseases
EP1615655B1 (en) Use of compositions for mucosal and oral administration comprising hcg fragments
Engel et al. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV
Delcros et al. Proteasome inhibitors as therapeutic agents: current and future strategies
Rajak et al. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity
EP4129318A1 (en) Protein-based pharmaceutical composition with neuroprotective, immunomodulating, anti-inflammatory and antimicrobial activity
Wójcik Ubiquitin-and proteasome-dependent pathway of protein degradation as an emerging therapeutic target
Saxena et al. ONCONASE® and its therapeutic potential
WO2005094423A2 (en) Selective inhibition of proteasomes of tuberculosis and other bacteria
Piccinini et al. Proteasomes as drug targets
Lu et al. Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells
US20240165196A1 (en) Beta-Lactamase Inhibitors
Chaithongyot Function of STAMBPL1 in Helicobacter pylori-associated cell death
Lindsten Functional studies of the ubiquitin-proteasome system using GFP-based reporters